TRCT
TRVI icon

Tower Research Capital (TRC)’s Trevi Therapeutics TRVI Stock Holding History

Tower Research Capital (TRC)’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.7K Buy
3,897
+728
+23% +$10.6K ﹤0.01% 2445
2026
Q1 		$37.8K Sell
3,169
-7,292
-70% -$81.6K ﹤0.01% 2985
2025
Q4 		$131K Buy
10,461
+7,675
+275% +$88.7K ﹤0.01% 1759
2025
Q3 		$25.5K Sell
2,786
-4,412
-61% -$33.1K ﹤0.01% 3086
2025
Q2 		$39.4K Buy
7,198
+4,884
+211% +$30.4K ﹤0.01% 3180
2025
Q1 		$14.6K Sell
2,314
-338
-13% -$1.61K ﹤0.01% 3286
2024
Q4 		$10.9K Sell
2,652
-1,251
-32% -$4K ﹤0.01% 3762
2024
Q3 		$13K Sell
3,903
-3,158
-45% -$9.39K ﹤0.01% 3545
2024
Q2 		$21K Buy
7,061
+6,451
+1,058% +$17.9K ﹤0.01% 3737
2024
Q1 		$2.1K Sell
610
-6,947
-92% -$15.5K ﹤0.01% 5118
2023
Q4 		$10.1K Buy
7,557
+1,104
+17% +$1.67K ﹤0.01% 4290
2023
Q3 		$14.1K Buy
6,453
+4,951
+330% +$11.2K ﹤0.01% 3717
2023
Q2 		$3.59K Buy
+1,502
New +$3.79K ﹤0.01% 5048
2022
Q4 		– Sell
-9,786
Closed -$15K – 6381
2022
Q3 		$15K Buy
9,786
+5,912
+153% +$19.4K ﹤0.01% 4180
2022
Q2 		$11K Sell
3,874
-5,603
-59% -$13.8K ﹤0.01% 4392
2022
Q1 		$21K Buy
9,477
+1,160
+14% +$1.2K ﹤0.01% 3499
2021
Q4 		$7K Buy
8,317
+3,514
+73% +$3.69K ﹤0.01% 4951
2021
Q3 		$7K Buy
4,803
+616
+15% +$1.09K ﹤0.01% 4676
2021
Q2 		$10K Buy
4,187
+2,950
+238% +$6.64K ﹤0.01% 4403
2021
Q1 		$3K Sell
1,237
-3,991
-76% -$11.7K ﹤0.01% 4928
2020
Q4 		$13K Buy
5,228
+3,821
+272% +$12.4K ﹤0.01% 4165
2020
Q3 		$6K Buy
+1,407
New +$6.61K ﹤0.01% 4313
2019
Q4 		– Sell
-2,344
Closed -$11K – 4366
2019
Q3 		$11K Buy
2,344
+1,142
+95% +$6.21K ﹤0.01% 2888
2019
Q2 		$9K Buy
+1,202
New +$10.4K ﹤0.01% 2632

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Tower Research Capital (TRC)'s TRVI Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Trevi Therapeutics (TRVI) stake by 23% in Q2 2026, buying an estimated $10.6K and bringing the position to 3,897 shares worth $72.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2445.

Tower Research Capital (TRC) first reported a position in TRVI in Q2 2019 and has held it in 24 quarters since. The position peaked at $131K in Q4 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Tower Research Capital (TRC) held 3,897 shares of Trevi Therapeutics worth $72.7K as of Q2 2026.
  • Tower Research Capital (TRC) bought 728 Trevi Therapeutics shares in Q2 2026, an estimated $10.6K.
  • Trevi Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2445 holding.
  • Tower Research Capital (TRC) first reported a position in Trevi Therapeutics in Q2 2019 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Trevi Therapeutics position peaked at $131K in Q4 2025.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.